Arrowhead Pharmaceuticals (ARWR) Return on Invested Capital: 2023-2025
- Arrowhead Pharmaceuticals' Return on Invested Capital rose 237.00% to 0.10% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.10%, marking a year-over-year increase of 237.00%. This contributed to the annual value of 0.16% for FY2025, which is 266.00% up from last year.
- Latest data reveals that Arrowhead Pharmaceuticals reported Return on Invested Capital of 0.10% as of Q3 2025, which was up 135.52% from -0.29% recorded in Q1 2025.
- Arrowhead Pharmaceuticals' Return on Invested Capital's 5-year high stood at 0.10% during Q3 2025, with a 5-year trough of -5.03% in Q4 2024.
- For the 3-year period, Arrowhead Pharmaceuticals' Return on Invested Capital averaged around -1.76%, with its median value being -1.30% (2023).
- Per our database at Business Quant, Arrowhead Pharmaceuticals' Return on Invested Capital slumped by 373bps in 2024 and then skyrocketed by 237bps in 2025.
- Arrowhead Pharmaceuticals' Return on Invested Capital (Quarterly) stood at -1.30% in 2023, then plummeted by 373bps to -5.03% in 2024, then soared by 237bps to 0.10% in 2025.
- Its Return on Invested Capital stands at 0.10% for Q3 2025, versus -0.29% for Q1 2025 and -5.03% for Q4 2024.
